Chicago Rivet & Machine Co.

SUGAR LAND, Texas--(BUSINESS WIRE)--CVR Partners, LP (NYSE: UAN), a manufacturer of ammonia and urea ammonium nitrate (UAN) solution fertilizer products, plans to release its third quarter 2026 earnings results on Tuesday, November 3, before the opening of trading on the New York Stock Exchange. The Partnership also will host a teleconference call on Tuesday, November 3, at 10 a.m. Eastern to discuss these results. This call, which will contain forward-looking information, will be webcast live.

SUGAR LAND, Texas--(BUSINESS WIRE)--CVR Energy, Inc. (NYSE: CVI) plans to release its third quarter 2026 earnings results on Tuesday, November 3, before the opening of trading on the New York Stock Exchange. The Company also will host a teleconference call on Tuesday, November 3, at 1 p.m. Eastern to discuss these results. This call, which will contain forward-looking information, will be webcast live and can be accessed on the Investor Relations section of CVR Energy's website at www.CVREnergy.

One CVR will attach to each outstanding share of Atossa common stock as of the close of business on October 19, 2026, and shares and CVRs will transfer together while stapled Shares issued after October 19, 2026 will also carry one attached CVR, subject to the terms of the CVR Agreement SEATTLE, Oct. 19, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need, today confirmed that each outstanding share of Atossa common stock will begin trading with one stapled contingent value right ("CVR") as of the close of business today, October 19, 2026. Under the terms of the Stapled Contingent Value Rights Agreement (the "CVR Agreement") with VStock Transfer, LLC, as rights agent, each share of Atossa common stock outstanding at the close of business on October 19, 2026 will receive, and have attached, one CVR.

CVR Energy (CVI) has delivered outsized returns, up 372.7% since March 2021, significantly outperforming the S&P 500. Favorable crack spreads, tight inventories, and geopolitical disruptions have driven strong revenue and margin expansion for CVI's petroleum and fertilizer segments. Despite recent strength, I maintain a soft ‘buy' rating, noting that forward valuation is reasonable but caution is warranted ahead of potentially mixed Q3 2026 results.

Shareholders would receive one CVR for each ATOS share held as of the record date or issued thereafter CVRs would entitle holders to 25% of net proceeds from monetization of Atossa's first qualifying priority review voucher, subject to a $50 million aggregate payment cap SEATTLE, Sept. 29, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need, today announced that its Board of Directors has approved a plan to issue one contingent value right ("CVR") for each share of Atossa common stock to enable shareholders to share in a portion of any proceeds received from the monetization of Atossa's first qualifying rare pediatric disease priority review voucher.

CVR Partners is uniquely positioned to benefit from Middle East supply disruptions, driving favorable domestic nitrogen fertilizer pricing and robust cash flows. UAN's operational moat stems from proprietary feedstock flexibility, low-cost production, and strategic plant locations, ensuring resilience against natural gas price volatility. Management's disciplined capital allocation, strong $187M liquidity, and self-funded growth underpin double-digit distribution yields and financial stability.

CVR Partners remains a buy as nitrogen fertilizer pricing strength and near-flawless Q2 execution have driven shares to nearly double since January 2024. UAN's structural cost advantage at Coffeyville is being enhanced via a feedstock diversification project, now expected to complete in 2027 for less than half the original estimate. Distributions will be lower in Q3 due to a planned East Chicago turnaround, but management's capital allocation prioritizes long-term cost advantages over maximizing near-term payouts.

Chicago Rivet and Machine Co. (NYSEAMERICAN:CVR - Get Free Report)'s stock price crossed below its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $10.27 and traded as low as $10.18. Chicago Rivet and Machine shares last traded at $10.18, with a volume of 746 shares